Oruka Therapeutics

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Super Micro Computer, Bakkt Holdings, MARA Holdings, Microstrategy, And Tesla Inc: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CHWY

HUMA

NYXH

ORKA

PPTA

RAPP

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

GameStop Corp.

BHIL

BSGM

CISO

CLEU

GDHG

IMTE

PTPI

SURG

THTX

TXMD

WINT

Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

Initiation

Analyst Ratings

CPRX

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Oruka Therapeutics Inc

Press Releases

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Health Care

Oruka Therapeutics to Present at Multiple November Investor Conferences

Earnings

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Abeona Therapeutics

Absci

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Celcuity

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Erasca

Heron Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sana Biotechnology

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Verastem

HC Wainwright & Co.

Wolfe Research

Stifel

Leerink Partners

Leerink Swann

Comments

Oruka Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell